Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody
Abstract
Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186YTE, for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 20, 2023
- Source ID
- 10.1093/infdis/jiad278
Entities
People
- Abhishek N Prasad
- Arumugapradeep Marimuthu
- Brent Yamamoto
- Chris Hu
- Courtney Woolsey
- Dafna Abelson
- Daniel J. Deer
- Do Kim
- Eric Ailor
- Hong Vu
- Jennifer Barajas
- Jennifer E. Peel
- Karla A. Fenton
- Kevin J Whaley
- Krystle N Agans
- Larry Zeitlin
- Lauren Stuart
- Natalie S. Dobias
- Robert W Cross
- Thomas W Geisbert
- Viktoriya Borisevich
- William S. Lawrence
Organizations
- Defense Threat Reduction Agency
- Mapp Biopharmaceutical
- National Institutes of Health
- United States Department of Health and Human Services
- University of Texas Medical Branch